Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT06211413
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
22 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • no intervention — OTHER
    no intervention

Study Details

Acalabrutinib and Zanabrutinib are highly effective drugs used to treat Chronic Lymphocytic Leukemia, but they are associated with high blood pressure and abnormal heart rhythms. SENTINEL is an observational study that will use wearable technology to monitor heart rhythm and blood pressures at home to better understand how frequently patients are experiencing high blood pressure and/or abnormal heart rhythms.

Key Dates

Start date
Feb 7, 2024
Status verified
Mar 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

Incidence of hypertension [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center at University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By condition
Atrial fibrillationLeukemia (other)Hypertension (high blood pressure)
By specialty
CardiologyHeart diseaseOncologyBlood cancer
By research site
Abramson Cancer Center at University of Pennsylvania· Philadelphia, PA

Related Studies